← The Wire
VRCANasdaq
Verrica Pharmaceuticals Inc.
Pharmaceutical Preparations · DE · CIK 1660334
Verrica Pharmaceuticals develops and commercializes clinician-administered therapies for dermatologic diseases, including skin cancers
red 8-K · 90d
$98M
Market cap
$6.50
Last close
-5.0%
1D
+15.3%
5D
67K
Volume
Price · last 39 sessions+2.2%
May 4L $5.59 · H $8.43Jun 29
174
Total filings
Jun 9, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteJun 9, 202610-Q10-QMay 12, 20268-KResults of OperationsMay 12, 2026DEFA14ADEFA14AApr 20, 2026DEF 14ADEF 14AApr 20, 202610-K10-KMar 11, 20268-KResults of OperationsMar 11, 20268-KExecutive ChangeDec 30, 2025SC 13D/ASC 13D/ADec 30, 20258-KMaterial Agreement · Equity IssuanceNov 24, 202510-Q10-QNov 14, 20258-KResults of OperationsNov 14, 202510-Q10-QAug 12, 20258-KResults of Operations · Company UpdateAug 12, 20258-KDelisting NoticeJul 30, 20258-KSecurity-Holder RightsJul 23, 20258-KMaterial Agreement · Reg FD DisclosureJul 1, 20258-KMaterial AgreementJun 12, 20258-KShareholder VoteJun 5, 202510-Q10-QMay 13, 20258-KResults of OperationsMay 13, 20258-KExecutive ChangeApr 25, 2025DEFA14ADEFA14AApr 22, 2025DEF 14ADEF 14AApr 22, 20258-KExecutive ChangeApr 2, 202510-K10-KMar 11, 20258-KResults of OperationsMar 11, 20258-KMaterial AgreementFeb 21, 20258-KDelisting NoticeJan 30, 20258-KExecutive ChangeDec 9, 20248-KMaterial Agreement · Company UpdateNov 21, 2024424B5424B5Nov 21, 20248-KCompany UpdateNov 20, 2024424B5424B5Nov 20, 202410-Q10-QNov 5, 20248-KExecutive Change · Results of OperationsNov 4, 20248-KDelisting Notice · Executive ChangeOct 8, 20248-KExit / Disposal CostsOct 1, 20248-KExecutive ChangeSep 27, 20248-KExecutive ChangeSep 6, 20248-KExecutive ChangeAug 27, 202410-Q10-QAug 14, 20248-KResults of Operations · Reg FD DisclosureAug 14, 20248-KMaterial AgreementAug 5, 20248-KMaterial AgreementJun 28, 20248-KShareholder VoteJun 10, 20248-KMaterial Agreement · Equity IssuanceMay 15, 202410-Q10-QMay 13, 20248-KResults of OperationsMay 13, 2024DEFA14ADEFA14AApr 19, 2024DEF 14ADEF 14AApr 19, 202410-K10-KFeb 29, 20248-KResults of OperationsFeb 29, 2024SC 13GVERRICA PHARMACEUTICALS INC.Feb 14, 20248-KReg FD DisclosureJan 8, 202410-Q10-QNov 9, 20238-KResults of OperationsNov 9, 202310-Q10-QAug 8, 20238-KResults of OperationsAug 8, 20238-KReg FD DisclosureJul 27, 20238-KMaterial Agreement · New Debt / ObligationJul 26, 20238-KReg FD Disclosure · Company UpdateJul 24, 20238-KShareholder VoteJun 8, 202310-Q10-QMay 9, 20238-KResults of OperationsMay 9, 2023DEFA14ADEFA14AApr 21, 2023DEF 14ADEF 14AApr 21, 202310-K10-KMar 6, 20238-KResults of OperationsMar 6, 2023424B5424B5Feb 22, 20238-KMaterial Agreement · Company UpdateFeb 21, 20238-KResults of Operations · Company UpdateFeb 21, 20238-KReg FD DisclosureFeb 2, 20238-KCompany UpdateJan 24, 2023424B5424B5Dec 19, 202210-Q10-QNov 7, 20228-KResults of OperationsNov 7, 20228-KReg FD DisclosureSep 14, 202210-Q10-QAug 11, 20228-KResults of OperationsAug 11, 2022
Insider Activity
◆ Cluster Buy · 5 insidersIn the 90 days to Nov 25, 2025: 5 insiders bought $18.0M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 25, 2025 | Manning Paul BDirector,TenPercentOwner | Buy | 2,750,762 | $4.24 | $11.7M |
| Nov 25, 2025 | Manning Paul BDirector,TenPercentOwner | Buy | 1,375,380 | $4.24 | $5.8M |
| Nov 25, 2025 | Rieger JaysonCEO and President | Buy | 94,311 | $4.24 | $400K |
| Nov 25, 2025 | Zawitz DavidChief Operating Officer | Buy | 10,000 | $4.24 | $42K |
| Nov 25, 2025 | Kirby John J.Interim CFO | Buy | 3,536 | $4.24 | $15K |
| Nov 25, 2025 | Rosenberg Noah L.CMO | Buy | 2,357 | $4.24 | $10K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance